Audrey Simonaggio
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Renal cell carcinoma treatment, CAR-T cell therapy research, Renal and related cancers, Ferroptosis and cancer prognosis
Most-Cited Works
- → Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer(2019)361 cited
- → Enhance the Immune Checkpoint Inhibitors Efficacy with Radiotherapy Induced Immunogenic Cell Death: A Comprehensive Review and Latest Developments(2021)65 cited
- → Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC)(2021)64 cited
- → The 2016–2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study(2020)59 cited
- → Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab(2020)54 cited
- → BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer(2020)41 cited
- → Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit(2020)40 cited
- → MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights(2022)34 cited
- → Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)(2023)31 cited
- → Preexisting autoantibodies as predictor of immune-related adverse events for advanced solid tumors treated with immune checkpoint inhibitors.(2022)24 cited